📄 medicine

Pharmacokinetic Characterization of the Gastrointestinal Acute Radiation Syndrome Mitigator YK-4-250 in Male and Female Mice Under Non-Irradiated and Partial Body Irradiation Conditions

This study characterizes the pharmacokinetic profile of the gastrointestinal acute radiation syndrome mitigator YK-4-250 in male and female mice, revealing that while radiation exposure significantly impairs systemic clearance and alters absorption kinetics in a dose- and sex-dependent manner, a higher 40 mg/kg dose effectively equalizes exposure between sexes, suggesting a need for adaptive dosing strategies in radiation-mitigative therapies.

Original authors: Julius O. Nyalwidhe, Vidya P. Kumar, Shimin Chen, Janette Lockett, Yali Kong, Sanchita P. Ghosh, David Mu, Milton L. Brown

Published 2026-07-06

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Julius O. Nyalwidhe, Vidya P. Kumar, Shimin Chen, Janette Lockett, Yali Kong, Sanchita P. Ghosh, David Mu, Milton L. Brown

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A "Rescue Vehicle" for Radiation Sickness

Imagine a new medicine called YK-4-250. Think of it as a specialized rescue vehicle designed to save people (or mice, in this study) from the severe damage caused by a massive radiation exposure, specifically the kind that hurts the stomach and intestines.

Before this rescue vehicle can be used in a real emergency, scientists need to know exactly how it behaves inside the body. They need to answer three questions:

How fast does it get to work? (Absorption)
How long does it stay in the system? (Clearance/Half-life)
Does it behave differently in men versus women? (Sex differences)

This study tested the rescue vehicle in mice under two conditions: normal health and after a heavy radiation hit. They also tested two different "fuel loads" (doses): a small one (20 mg/kg) and a big one (40 mg/kg).

1. The "Normal Day" Test (Non-Irradiated Mice)

When the mice were healthy and hadn't been exposed to radiation, the medicine behaved somewhat predictably, but with a twist based on gender.

The Speed: In both male and female mice, the medicine was absorbed quickly, hitting its peak speed in the bloodstream in just 1 hour. It was like a sprinter taking off immediately.
The Fuel Load: When they doubled the dose from small to big, the medicine didn't just double in the body; it actually exploded in quantity. This suggests the body's "waste disposal" system got overwhelmed and couldn't clear the extra medicine fast enough.
The Gender Gap: In healthy mice, female mice held onto the medicine much longer than males.
- Analogy: Imagine two people drinking a large soda. The male clears it quickly and pees it out. The female, however, seems to have a "sticky" system where the soda lingers in her stomach and bloodstream much longer. At the higher dose, the medicine stayed in females more than twice as long as in males.

2. The "Disaster Zone" Test (Irradiated Mice)

Then, the scientists exposed the mice to a lethal dose of radiation (14.6 Gy) that damages the gut and liver. This is where things got very interesting. The radiation acted like a chaotic storm that changed the rules of the road.

Scenario A: The Small Dose (20 mg/kg)

When the mice were hit with radiation and given the small dose, the gender gap became massive.

Females: The medicine hit them fast (1 hour) but then got stuck. Their bodies stopped clearing it effectively. The medicine stayed in their system twice as long as it did in males.
- Analogy: Imagine a highway after a storm. The female mice's highway has a massive traffic jam (clearance stopped), so the rescue vehicle is stuck in gridlock for hours.
Males: The radiation slowed them down a bit (peak at 3 hours), but they still managed to clear the medicine relatively quickly.
- Result: If you gave the same small dose to a male and a female after radiation, the female would end up with double the amount of medicine in her body compared to the male.

Scenario B: The Big Dose (40 mg/kg)

When they increased the dose to 40 mg/kg under radiation, something surprising happened: The gender gap disappeared.

The "Equalizer" Effect: The massive stress of the radiation and the high dose of medicine seemed to "break" the body's ability to clear the drug for everyone. Both males and females ended up with almost the exact same amount of medicine in their bodies over time.
The New Difference: The only thing that changed was timing.
- Males: Still absorbed the medicine relatively quickly (peak at 3 hours).
- Females: The radiation caused a severe delay. It took them 6 hours to even reach the peak level of medicine in their blood.
- Analogy: Imagine the rescue vehicle trying to enter a city during a massive blackout. For the males, the traffic lights are slow but working. For the females, the traffic lights are completely broken, and the vehicle has to wait in a long line for hours before it can even enter the city.

3. Why Did This Happen? (The Mechanism)

The paper suggests that radiation acts like a "system shutdown" for the body's cleaning crew.

The Liver: Radiation causes inflammation that tells the liver's enzymes (the workers that break down drugs) to stop working.
The Gut: Radiation damages the lining of the stomach and intestines, slowing down how fast food or medicine moves through the system.
The Result: Because the "cleaning crew" is down, the medicine stays in the body much longer, leading to higher exposure.

4. What Does This Mean for the Future?

The authors conclude that you cannot treat a male and a female exactly the same way after a radiation accident if you are using this specific medicine.

At the Low Dose: Females are at risk of getting too much medicine because their bodies can't clear it. They might need a smaller dose or less frequent dosing. Males might need more because they clear it too fast.
At the High Dose: The total amount of medicine is the same for both, but females wait much longer for it to start working. If the medicine is needed immediately to save a life, waiting 6 hours for it to kick in in females might be dangerous. The authors suggest that for females, a different delivery method (like an IV injection) might be needed to bypass the slow gut.

Summary

This study is like a traffic report for a new ambulance. It found that:

Healthy days: Women hold onto the ambulance longer than men.
Disaster days (Radiation): The roads are broken.
- With a small load, women get stuck in traffic for hours (too much medicine), while men move faster.
- With a big load, everyone is stuck in the same traffic jam, but women take twice as long to even get out of the driveway.

The main takeaway is that one size does not fit all. To save lives after radiation, doctors will need to adjust the dose and timing based on whether the patient is male or female.

Technical Summary: Pharmacokinetic Characterization of YK-4-250 in Male and Female Mice Under Non-Irradiated and Partial Body Irradiation Conditions

Problem Statement
The translation of novel therapeutic candidates from preclinical discovery to clinical application requires a granular understanding of their in vivo pharmacokinetic (PK) behavior under both baseline physiological conditions and pathophysiological stress states. Specifically, for countermeasures targeting Gastrointestinal Acute Radiation Syndrome (GI-ARS), the impact of radiation exposure on drug disposition remains a critical knowledge gap. Acute radiation induces systemic oxidative stress and inflammatory cascades (e.g., IL-1, IL-6, TNF-α) that can disrupt gastrointestinal absorption dynamics, alter plasma protein binding, and suppress hepatic metabolic capacities (Phase I/II enzymes). Furthermore, sexual dimorphism is a known factor in drug metabolism and adverse event incidence, yet comparative PK data for radiation mitigators across sexes in irradiated versus non-irradiated states is largely uncharacterized. This study addresses the need to define the PK profile of YK-4-250, a long-acting Tempol-conjugated angiotensin receptor blocker (TCARB), to determine if radiation exposure and biological sex necessitate adaptive dosing strategies.

Methodology
The study utilized a non-compartmental analysis (NCA) approach to characterize the PK profile of YK-4-250 in C57BL/6 mice (12–14 weeks old).

Experimental Design: Mice were stratified into eight cohorts based on sex (male/female), irradiation status (non-irradiated vs. Partial Body Irradiation [PBI]), and dosage (20 mg/kg vs. 40 mg/kg).
Radiation Model: PBI was administered at 14.6 Gy (LD50/30) using a 4 MV photon beam from a linear accelerator, with 2.5% bone marrow sparing (one hind leg excluded).
Administration: YK-4-250 was administered via oral gavage as a suspension in 5% DMSO/0.5% Tween 80.
Data Collection: Serial blood samples were collected at 0, 1, 3, 6, 12, 24, 48, and 72 hours post-dose. Plasma concentrations were quantified using a validated LC-MS/MS method with a linear calibration range of 0.02–18.0 µg/mL.
Analysis: Key PK parameters ( $C_{max}$ , $T_{max}$ , $AUC_{last}$ , $AUC_{inf}$ , $t_{1/2}$ , $CL$, and $V_z$ ) were calculated using standard NCA methods.

Key Contributions and Results
The study provides the first systematic characterization of YK-4-250's PK behavior under radiation stress, revealing significant interactions between dose, sex, and irradiation status.

Baseline (Non-Irradiated) Kinetics:
- Absorption: Oral absorption was rapid in all non-irradiated cohorts, with a $T_{max}$ of 1.0 hour for both sexes and doses.
- Dose Proportionality: Increasing the dose from 20 to 40 mg/kg resulted in a supra-linear expansion in exposure ( $AUC_{last}$ ), suggesting saturation of baseline clearance pathways.
- Sex Differences: At 40 mg/kg, female mice exhibited significantly higher systemic exposure ( $AUC_{inf}$ increased by ~49.7%) and a prolonged terminal half-life ( $t_{1/2}$ increased by 111.65%) compared to males. This was driven by a 33.21% reduction in systemic clearance ($CL$) and a 41.37% increase in apparent volume of distribution ( $V_z$ ) in females.
- Note: At 20 mg/kg, baseline sex differences were confounded by poor terminal phase capture in males (high extrapolation percentage), rendering definitive conclusions on clearance at this dose unreliable.
Impact of Radiation (20 mg/kg Dose):
- Divergence: Radiation exposure fundamentally altered kinetics, creating a stark sex-based divergence. Irradiated females exhibited significantly higher and prolonged exposure compared to irradiated males.
- Mechanism: Irradiated females showed a 50.1% reduction in systemic clearance and an 85.2% prolongation of $t_{1/2}$ compared to irradiated males. Consequently, total projected exposure ( $AUC_{inf}$ ) in females was double that of males (8.80 vs. 4.37 µg∙hr/mL).
- Absorption: Contrary to the delayed absorption seen at higher doses, irradiated females at 20 mg/kg reached peak concentration ( $T_{max}$ ) faster (1 hr) than irradiated males (3 hr).
The "Physiological Equalizer" Effect (40 mg/kg Dose):
- Convergence: At the 40 mg/kg dose under radiation, the severe pathophysiological stress acted as a "physiological equalizer," eliminating the exposure gaps observed at 20 mg/kg. Total exposure ( $AUC_{inf}$ ) and clearance rates converged to nearly equivalent values between sexes (~22 µg∙hr/mL).
- Prolonged Retention: Both sexes experienced a dramatic extension of terminal half-life (22.51 hr in males, 18.75 hr in females), indicating a universal suppression of clearance mechanisms, likely due to the downregulation of hepatic metabolic pathways.
- Sex-Specific Absorption Delay: The primary differentiating feature at this dose was a significant delay in female absorption. The $T_{max}$ for irradiated females doubled from 3.0 hours (males) to 6.0 hours, suggesting a sex-specific delay in gastrointestinal transit or uptake.

Significance and Claims
The authors claim that these findings establish a vital translational foundation for the medical countermeasure community by demonstrating that radiation exposure systematically disrupts the biological systems responsible for drug disposition. The study concludes that:

Dose-Dependent Sex Differences: Radiation-induced PK alterations are highly dose-dependent. At lower doses (20 mg/kg), sex-based differences in clearance and exposure are pronounced, potentially necessitating sex-stratified dosing (e.g., dose reduction or extended intervals for females to avoid toxicity).
Absorption Delays: At higher doses (40 mg/kg), while total exposure is similar between sexes, the delayed absorption in females ( $T_{max}$ = 6 hr) could compromise the rapid onset of action required for acute radiation countermeasures.
Clinical Implications: Standard therapeutic regimens developed for uninjured states may not be applicable to irradiated subjects without risking accumulation-related toxicities or delayed efficacy. The authors suggest that tailored, sex-specific dosing and scheduling strategies (potentially including alternative administration routes for females to bypass absorption delays) must be evaluated in higher species to optimize the therapeutic index of YK-4-250.

The paper emphasizes that these results are specific to the murine model and YK-4-250, serving as a prerequisite for defining the compound's therapeutic window and safety margins in future clinical development.